74
Participants
Start Date
July 26, 2017
Primary Completion Date
December 29, 2020
Study Completion Date
April 22, 2021
Filgotinib
Tablet(s) administered orally
Placebo to match filgotinib
Tablet(s) administered orally
Prednisone
Tablet(s) administered orally
Auckland Eye, Remuera
Lions Eye Institute, Nedlands
Mid Atlantic Retina, Philadelphia
Wake Forest Baptist Medical Center, Winston-Salem
Duke University Eye Center, Durham
Cleveland Clinic Foundation-Cole Eye Institute, Cleveland
Associated Retinal Consultants PC, Royal Oak
university of Wisconsin-Madison, Madison
Illinois Retina Associates, Oak Park
Northwestern Medical Group, Chicago
Texas Retina Associates - Fort Worth, Fort Worth
Foresight Studies, LLC, San Antonio
Colorado Retina Associates PC, Golden
Hadassah Medical Center, Jerusalem
Stanford Byers Eye Institute, Palo Alto
Oregon Health Science University-Casey Eye Institute, Portland
Ophthalmic Consultants of Boston, Boston
Metropolitan Eye Research and Surgery Institute, Palisades Park
Retina Consultants, Vancouver
St. Franziskus Hospital, Münster
Moorfields Eye Hospital NHS Foundation Trust, London
Royal Liverpool University Hospital, Liverpool
Central Mancester Hospitals NHS Foundation Trust, Manchester Royal Eye Hospital, Manchester
Eye Research Group Oxford, Oxford Eye Hospital, Oxford
Lead Sponsor
Collaborators (1)
Gilead Sciences
INDUSTRY
Galapagos NV
INDUSTRY